Specific determinants of conantokins that dictate their selectivity for the NR2B subunit of N-methyl-d-aspartate receptors

Neuroscience

Volumn 170, Issue 3, 2010, Pages 703-710

  Sheng, Z ^a   Prorok, M ^a   Castellino, F J ^a  

^a UNIVERSITY OF NOTRE DAME   (United States)

Author keywords

Conantokins; Electrophysiology; Ion channels; NMDAR antagonists; NMDAR subtypes

Indexed keywords

4 CARBOXYGLUTAMIC ACID; CONANTOKIN G; CONANTOKIN R; CONANTOKIN T; N METHYL DEXTRO ASPARTIC ACID RECEPTOR 1; N METHYL DEXTRO ASPARTIC ACID RECEPTOR 1A; N METHYL DEXTRO ASPARTIC ACID RECEPTOR 1B; N METHYL DEXTRO ASPARTIC ACID RECEPTOR 2A; N METHYL DEXTRO ASPARTIC ACID RECEPTOR 2B; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; UNCLASSIFIED DRUG;

AMINO ACID SUBSTITUTION; AMINO TERMINAL SEQUENCE; ARTICLE; CELL STRAIN HEK293; CONTROLLED STUDY; DRUG DESIGN; DRUG MECHANISM; DRUG SELECTIVITY; DRUG SYNTHESIS; GENE DELETION; HUMAN; HUMAN CELL; POINT MUTATION; PRIORITY JOURNAL; RECEPTOR BLOCKING;

AMINO ACID SEQUENCE; CONOTOXINS; EXCITATORY AMINO ACID ANTAGONISTS; HEK293 CELLS; HUMANS; MOLLUSK VENOMS; PATCH-CLAMP TECHNIQUES; PEPTIDES; POINT MUTATION; RECEPTORS, N-METHYL-D-ASPARTATE; TRANSFECTION;

EID: 79953236709     PISSN: 03064522     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neuroscience.2010.07.056     Document Type: Article

References (30)

1. Blandl T., Warder S.E., Prorok M., Castellino F.J. Structure-function relationships of the NMDA receptor antagonist peptide, conantokin-R. FEBS Lett 2000, 470:139-146.
2. Blandl T., Zajicek J., Prorok M., Castellino F.J. Sequence requirements for the N-methyl-D-aspartate receptor antagonist activity of conantokin-R. J Biol Chem 2001, 276:7391-7396.
3. Chatterton J.E., Awobuluyi M., Premkumar L.S., Takahashi H., Talantova M., Shin Y., Cui J.K., Tu S.C., Kevin A.S.K., Nakanishi N., Tong G., Lipton S.A., Zhang D.X. Excitatory glycine receptors containing the NR3 family of NMDA receptor subunits. Nature 2002, 415:793-798.
4. Cnudde S.E., Prorok M., Dai Q., Castellino F.J., Geiger J.H. The crystal structures of the calcium-bound con-G and con-T[K7gamma] dimeric peptides demonstrate a metal-dependent helix-forming motif. J Am Chem Soc 2007, 129:1586-1593.
5. Dai Q., Sheng Z., Geiger J.H., Castellino F.J., Prorok M. Helix-helix interactions between homo- and heterodimeric gamma-carboxyglutamate-containing conantokin peptides and their derivatives. J Biol Chem 2007, 282:12641-12649.
6. Donevan S.D., McCabe R.T. Conantokin G is an NR2B-selective competitive antagonist of N-methyl-D-aspartate receptors. Mol Pharmacol 2000, 58:614-623.
7. Furukawa H., Singh S.K., Mancusso R., Gouaux E. Subunit arrangement and function in NMDA receptors. Nature 2005, 438:185-192.
8. Gowd K.H., Twede V., Watkins M., Krishnan K.S., Teichert R.W., Bulaj G., Olivera B.M. Conantokin-P, an unusual conantokin with a long disulfide loop. Toxicon 2008, 52:203-213.
9. Grimwood S., Le Bourdelles B., Whiting P.J. Recombinant human NMDA homomeric NR1 receptors expressed in mammalian cells form a high-affinity glycine antagonist binding site. J Neurochem 1995, 64:525-530.
10. Haack J.A., Rivier J., Parks T.N., Mena E.E., Cruz L.J., Olivera B.M. Conantokin-T. A gamma-carboxyglutamate containing peptide with N-methyl-D-aspartate antagonist activity. J Biol Chem 1990, 265:6025-6029.
11. Jimenez E.C., Donevan S., Walker C., Zhou L.M., Nielsen J., Cruz L.J., Armstrong H., White H.S., Olivera B.M. Conantokin-L, a new NMDA receptor antagonist: determinants for anticonvulsant potency. Epilepsy Res 2002, 51:73-80.
12. Klein R.C., Prorok M., Castellino F.J. Direct binding properties of conantokins to native N-methyl-D-aspartate receptors. J Pept Res 2003, 61:307-317.
13. Klein R.C., Prorok M., Galdzicki Z., Castellino F.J. The amino acid residue at sequence position 5 in the conantokin peptides partially governs subunit-selective antagonism of recombinant N-methyl-D-aspartate receptors. J Biol Chem 2001, 276:26860-26867.
14. Klein R.C., Warder S.E., Galdzicki Z., Castellino F.J., Prorok M. Kinetic and mechanistic characterization of NMDA receptor antagonism by replacement and truncation variants of the conantokin peptides. Neuropharmacology 2001, 41:801-810.
15. Laube B., Hirai H., Sturgess M., Betz H., Kuhse J. Molecular determinants of agonist discrimination by NMDA receptor subunits: analysis of the glutamate binding site on the NR2B subunit. Neuron 1997, 18:493-503.
16. Ma Q., Hargreaves R.J. Localization of N-methyl-D-aspartate NR2B subunits on primary sensory neurons that give rise to small-caliber sciatic nerve fibers in rats. Neuroscience 2000, 101:699-707.
17. McIntosh J., Olivera B.M., Cruz L., Gray W. g-Carboxyglutamate in a neuroactive toxin. J Biol Chem 1984, 259:14343-14346.
18. Merchant R.E., Bullock M.R., Carmack C.A., Shah A.K., Wilner K.D., Ko G., Williams S.A. A double-blind, placebo-controlled study of the safety, tolerability and pharmacokinetics of CP-101,606 in patients with a mild or moderate traumatic brain injury. Ann N Y Acad Sci 1999, 890:42-50.
19. Prorok M., Castellino F.J. Structure-function relationships of the NMDA receptor antagonist conantokin peptides. Curr Drug Targets 2001, 2:313-322.
20. Prorok M., Warder S.E., Blandl T., Castellino F.J. Calcium binding properties of synthetic g-carboxyglutamic acid containing marine cone snail "sleeper" peptides, conantokin-G and conantokin-T. Biochemistry 1996, 35:16528-16534.
21. Sheng Z., Dai Q., Prorok M., Castellino F.J. Subtype-selective antagonism of N-methyl-D-aspartate receptor ion channels by synthetic conantokin peptides. Neuropharmacology 2007, 53:145-156.
22. Teichert R.W., Jimenez E.C., Twede V., Watkins M., Hollmann M., Bulaj G., Olivera B.M. Novel conantokins from conus parius venom are specific antagonists of NMDA receptors. J Biol Chem 2007, 282:36905-36913.
23. Twede V., Teichert R., Walker C., Gruszczynski P., Kazmierkiewicz R., Bulaj G., Olivera B. Conantokin-Br from Conus brettinghami and selectivity determinants for the NR2D subunit of the NMDA receptor. Biochemistry 2009, 48:4063-4073.
24. Warder S.E., Blandl T., Klein R.C., Castellino F.J., Prorok M. Amino acid determinants for NMDA receptor inhibition by conantokin-T. J Neurochem 2001, 77:812-822.
25. Wei J., Dong M., Xiao C., Jiang F., Castellino F.J., Prorok M., Dai Q. Conantokins and variants derived from cone snail venom inhibit naloxone-induced withdrawal jumping in morphine-dependent mice. Neurosci Lett 2006, 405:137-141.
26. White H.S., McCabe R.Y., Armstrong H., Donevan S.D., Cruz L.J., Abogadie F.C., Torres J., Rivier J.E., Paarmann I., Hollmann M., Olivera B.M. In vitro and in vivo characterization of conantokin-R, a selective NMDA receptor antagonist isolated from the venom of the fish-hunting snail Conus radiatus. J Pharmacol Exp Ther 2000, 292:425-432.
27. Williams A.J., Dave J.R., Lu X.M., Ling G., Tortella F.C. Selective NR2B NMDA receptor antagonists are protective against staurosporine-induced apoptosis. Eur J Pharmacol 2002, 452:135-136.
28. Wolosker H. D-serine regulation of NMDA receptor activity. Sci STKE 2006, 2006:pe41.
29. Xi G., Hua Y., Keep R.F., Younger J.G., Hoff J.T. Brain edema after intracerebral hemorrhage: the effects of systemic complement depletion. Acta Neurochir Suppl 2002, 81:253-256.
30. Xiao C., Huang Y., Dong M., Hu J., Hou S., Castellino F.J., Prorok M., Dai Q. NR2B-selective conantokin peptide inhibitors of the NMDA receptor display enhanced antinociceptive properties compared to non-selective conantokins. Neuropeptides 2008, 42:601-609.